Fairvalue-Calculator Fairvalue-Calculator

IHHHF (IHHHF) Fair Value & Analysis

Healthcare · US · Market cap $15.1B

Price$1.71
Fair Value$1.26
Upside-26.3%
Quality85/100
Evidence: Medium Range $0.6900 – $1.26

Analysis

IHHHF (IHHHF) currently trades at $1.71, while our model-based Fair Value estimate is $1.26 — implying the stock looks roughly 26.3% overvalued today. We read business quality at 85/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

IHH Healthcare Berhad, an investment holding company, offers healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Europe, and internationally. It provides primary care services, such as outpatient treatment, check-ups, vaccinations, preventive care, and patient education services. The company also offers secondary care facilities, including medical emergencies and acute treatment, as well as specialist consultation, diagnostics, and lab services; tertiary care services comprising specialist consultative care, advanced treatment, complex surgery, and inpatient care services; and quaternary care services, such as organ transplants, neurosurgery, cardiac surgery, and reconstructive plastic surgery. In addition, it provides ancillary services, including diagnostics, laboratory testing, radiology, physiotherapy, and integrated rehabilitation and advanced molecular diagnostics services. Further, the company offers medical education; train and develop nurses, doctors, c…

Open the full interactive analysis →

Similar stocks

HCA Healthcare, Inc (H1CA34) -73% Fresenius SE (FSNUY) -27% 5225 (5225) -70% Tenet Healthcare Corporation (THC) +74% Rede D'Or São Luiz S.A (RDOR3) -7% Fresenius Medical Care AG (FMS) +92%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.